Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century

Vox Sanguinis

Volumn 100, Issue 1, 2011, Pages 92-98

  Dwyre, D M ^a   Fernando, L P ^a   Holland, P V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis B; Hepatitis C; HIV; Pathogen inactivation; Transfusion transmitted infections

Indexed keywords

BLOOD DONOR; BLOOD TRANSFUSION; DONOR SELECTION; FALSE NEGATIVE RESULT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; DNA, VIRAL; DONOR SELECTION; HEPATITIS B; HEPATITIS C; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES;

EID: 78650359956     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01426.x     Document Type: Review

References (45)

1. Dwyre DM, Holland PV: Hepatitis viruses; in Barbara JAJ, Regan FAM, Contreras MC (eds): Transfusion Microbiology. Cambridge, Cambridge University Press, 2008:9-23
2. NIH consensus development panel on infectious disease testing for blood transfusions: Infectious disease testing for blood transfusions. JAMA 1995; 274:1374-1379
3. Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609-1620
4. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495-1504
5. Schmidt M, Korn K, Nübling CM, et al. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009; 49:1836-1844
6. Niederhauser C, Weingand T, Candotti D, et al. Fatal outcome of a hepatitis B virus transfusion-transmitted infection. Vox Sang 2010; 98:504-507
7. Kleinman SH, Lelie N, Busch MP: Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49:2454-2486
8. Katz L, Strong DM, Tegtmeier G, et al. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen. Transfusion 2008; 48:2315-2322
9. Reesink HW, Engelfriet CP, Henn G, et al. Occult hepatitis B infections in blood donors. Vox Sang 2008; 94:153-166
10. Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007; 47:1197-1205
11. Komiya Y, Katayama K, Yugi H, et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 42:286-294
12. Dettori S, Candido A, Kondili LA, et al. Identification of low HBV-DNA levels by nucleic amplification test (NAT) in blood donors. J Infect 2009; 59:128-133
13. Kenny Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340:1228-1233
14. Bernardin F, Tobler L, Walsh I, et al. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008; 47:1446-1452
15. Sosa-Jurado F, Santos-Lopez G, Guzman-Flores B, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 2010; 7:18
16. Hitziger T, Schmidt M, Schottstedt V, et al. Cellular immune response to hepatitis C virus (HCV) in nonviremic blood donors with indeterminate anti-HCV reactivity. Transfusion 2009; 49:1306-1313
17. Bes M, Esteban JI, Casamitjana N, et al. Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion 2009; 49:1296-1305
18. Widell A, Busch M: Exposed or not exposed - that is the question: evidence for resolving and abortive hepatitis C virus infections in blood donors. Transfusion 2009; 49:1277-1281
19. Melve GK, Myrmel H, Eide GE, et al. Evaluation of the persistence and characteristics of indeterminate reactivity against hepatitis C virus in blood donors. Transfusion 2009; 49:2359-2365
20. Kamel H, Johnson S, Piggott T, et al. Blood center response to public health concern due to unsafe injection practices at an endoscopy clinic. Transfusion 2008; 48(Suppl. 2):248A-249A
21. Kretzschmar E, Chudy M, Nuebling CM, et al. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays. Vox Sang 2007; 92:297-301
22. Tuke PW, Grant PR, Waite J, et al. Hepatitis C virus window-phase infections: closing the window on hepatitis C virus. Transfusion 2008; 48:594-600
23. Nubling CM, Heiden M, Chudy M, et al. Experience of mandatory nuclei acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009; 49:1850-1858
24. Vermeulen M, Lelie N, Sykes W, et al. Impact of individual donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009; 49:1115-1125
25. Gottlieb MS, Schanker HM, Fan PT, Saxon A, Weisman JD: Pneumocystis pneumonia, Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30:250
26. Ammann AJ, Cowan MJ, Weintrub P, et al. Acquired immunodeficiency in an infant: possible transmission by means of blood products. Lancet 1983; 8331:956-958
27. Busch MP, Young MJ, Samson SM, et al. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991; 31:4-11
28. Gallo RC, Montagnier L: The discovery of HIV as the cause of AIDS. N Engl J Med 2003; 349:2283-2285
29. Kopko P, Fernando L, Bonney EN, et al. HIV transmissions from a window period Platelet donation. Am J Clin Pathol 2001; 116:562-566
30. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000; 284:238-240
31. Harritshoj LH, Dickmeiss E, Hansen MB, et al. Transfusion-transmitted human immunodeficiency virus infection by a Danish blood donor with a very low viral load in the preseroconversion window phase. Transfusion 2008; 48:2026-2028
32. Delwart EL, Kalmin ND, Jones TS, et al. First report of human immunodeficiency virus via an RNA-screened blood donation. Vox Sang 2004; 86:171-177
33. Phelps R, Robbins K, Liberti T, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004; 44:929-933
34. Najioullah F, Barlet V, Renaudier P, et al. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations. J Med Virol 2004; 73:347-349
35. Ferreira MC, Nel TJ: Differential transmission of human immunodeficiency virus (HIV) via blood components from an HIV-infected donor. Transfusion 2006; 46:156-157
36. Gonçales TT, Sabino EC, Salles NA, et al. HIV Testing and Confidential Unit Exclusion users in São Paulo, Brazil. Transfusion 2009; 49(Suppl. 3):4A
37. Corash L: Pathogen reduction technology: methods, status of clinical trials and future prospects. Curr Hematol Rep 2003; 2:495-502
38. Lin L, Hanson CV, Alter HJ: Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005; 45:580-590
39. Takeda H, Matsubayashi K, Sakata H, et al. A nationwide survey for prevalence of hepatitis E virus antibody in qualified blood donors in Japan. Vox Sang 2010; 99:307-313
40. Dichtelmueller HO, Biesert L, Fabbrizzi F, et al. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from plasma protein therapeutics association member companies. Transfusion 2009; 49:1931-1943
41. Goodrich RP, Custer B, Keil S, et al. Defining "adequate" pathogen reduction performance for transfused blood components. Transfusion 2010; 50:1827-1837
42. Steil L, Thiele T, Hammer E, et al. Proteomic characterization of freeze-dried human plasma: providing treatment of bleeding disorders without the need for a cold chain. Transfusion 2008; 48:2356-2363
43. Prowse CV, Murphy WG: Kills 99% of known germs. Transfusion 2010; 50:1636-1639
44. Mufti NA, Erickson AC, North AK: Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38:14-19
45. Goodrich RP, Doane S, Reddy HL: Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38:20-30